Skip to main content
Equibles
CYTK logo

CYTK · Cytokinetics Inc · Metrics

Track CYTK — free

Use CYTK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CYTK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$61.23 -1.10 (-1.76%) At close · Oct 23
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.51B
Shares
139.02M
Volume · Oct 23 985.84K Avg daily vol (3M) 1.96M

CYTK metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$61.23
Market cap
$8.51B

Price action

20 metrics
Price change (1W)
-1.2%
Price change (30D)
-5.3%
Price change (3M)
-24.2%
Price change (6M)
-6.3%
Price change (YTD)
-3.6%
Price change (1Y)
+6.5%
Trailing year
Price change (5Y)
+65.4%
52-week high
$87.26
52-week low
$57.50
Change from 52-week high
-29.8%
Change from 52-week low
+6.5%
Annualized volatility
42.4%
Annualized volatility (3M)
34.1%
Beta
0.8
RSI (14D)
36.4
Price vs SMA 50
-11.2%
Price vs SMA 200
-12.7%
Avg volume (3M)
1.96M
Relative volume
0.5
Average dollar volume
$138.44M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
139.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
126.1×
reciprocal yield 0.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
125.8×
reciprocal yield 0.8%
P / book
—
FCF yield
-6.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
698.1×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
531.8×
reciprocal yield 0.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-1,046.1%
Trailing 12 months
Net margin
-1,321.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$707.91M
Net income (TTM)
−$894.00M
Trailing 12 months
Diluted EPS (TTM)
$-7.23
FCF margin
-858.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$534.87
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5,692.66
EBITDA per diluted share (TTM)
$-5,592.07
Net income per diluted share (TTM)
$-7,222.92
Operating cash flow per diluted share (TTM)
$-4,451.20
Free cash flow per diluted share (TTM)
$-4,656.18
Capital expenditures per diluted share (TTM)
$204.98
R&D per diluted share (TTM)
$3,227.76
Stock compensation per diluted share (TTM)
$1,021.92
Book value per share
$-5.37

Growth

11 metrics
Revenue growth YoY
-57.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$67.67M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.6%
Year over year · more shares
Revenue CAGR (3Y)
-2.4%
Revenue CAGR (5Y)
+9.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-46.5%
Debt / equity
—
Current ratio
6.7
EBITDA (TTM)
−$695.36M
Free cash flow (TTM)
−$580.72M
Quick ratio
6.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$20.29M
Latest balance sheet
Cash & equivalents
$255.27M
Total assets
$1.92B
Total debt
$275.56M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$555.45M
Capital expenditures (TTM)
$25.26M
R&D (TTM)
$400.96M
SG&A (TTM)
—
Stock compensation (TTM)
$127.31M
R&D / revenue
592.5%
Stock compensation / revenue
188.1%

Ownership (13F)

9 metrics
13F filers
490
13F filer change QoQ
+38
Institutional ownership
120.7%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+7.6%
Holder tenure
14.2
Price vs estimated holder cost
+54.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.2%

Short interest

3 metrics
Short interest
13.9%
Latest settlement · 8.4 days to cover
Days to cover
8.4d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$13.54M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 63 filings 63 filers Visit website Investor relations